Analysis of the Correlation between Biological Effects of EGFR Exon 19 and 21 Mutations and Clinical and Imaging Features in Lung Adenocarcinoma
DOI:
https://doi.org/10.53469/jcmp.2025.07(01).24Keywords:
Lung adenocarcinoma, EGFR mutation, Chest CT, Imaging FeaturesAbstract
Objective: To analyze the correlation between Biological Effects of EGFR Exon 19 and 21 Mutations and Clinical and Imaging characteristics in Lung Adenocarcinoma. Methods: The clinical and imaging data of patients with lung adenocarcinoma who had undergone genetic testing in Baotou Cancer Hospital from July 2021 to May 2024 were retrospectively collected, and chest CT examination was performed before treatment to evaluate the EGFR mutant wild type and subtype (exon 19 and 21) of lung adenocarcinoma patients clinical and imaging features, and the characteristics were compared between groups. Univariate analysis was used to analyze the differences and statistically significant indicators into binary logistic regression analysis to screen out independent predictors. Results: Compared with wild-type EGFR19 mutations, females, small lesions with maximum diameter, spiculation, pleural indentation, and low INCTR were more common in the EGFR 19 mutation group, and males, larger lung lesions with maximum diameter, no spiculation, no pleural indentation, and higher INCTR were more common in wild-type (all p <0.5). stic regression analysis showed that the diameter of small lesions (OR=90.825, 95%CI 2.023-4078.299, P=0.020) and INCTR (OR=0.692, 95%C 0.516-0.927, P=0.014) was a risk factor for EGFR19 mutation. In the comparison of EGFR21 mutation and wild-type, female, non-smoking patients, vessel convergeence sign, and low INCTR were more common in the EGFR 21 mutation group, and binary logistic regression analysis showed vessel convergeence sign (OR=18.582, 95%CI 1.848-186.870, P=0.013) and INCTR (OR=0.793, 95%CI 0.687-0.915, P=0.002) were risk factors for EGFR21 mutation.
References
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022 [J]. Journal of the National Cancer Center, 2024.
Greenhalgh J, Dwan K, Boland A, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer [J]. Cochrane Database of Systematic Reviews, 2016.
Hu D, Zhou Y-Y, Ma H-B, et al. Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis [J]. BMC Pulmonary Medicine, 2023, 23(1).
Tavernari D, Borgeaud M, Liu X, et al. Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief Report [J]. Journal of Thoracic Oncology, 2024.
Li W-Q, Cui J-W. Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments [J]. Journal of Cancer Research and Clinical Oncology, 2020, 146(9): 2329–2338.
Batra U, Biswas B, Prabhash K, et al. Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer [J]. BMJ Open Respiratory Research, 2023, 10(1): e001492.
Liao C, Liu X, Zhang C, et al. Tumor hypoxia: From basic knowledge to therapeutic implications [J]. Seminars in Cancer Biology, 2023, 88: 172–186.
Lequeux A, Noman M Z, Xiao M, et al. Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy [J]. Oncogene, 2021, 40(28): 4725–4735.
Godet I, Shin Y J, Ju J A, et al. Fate-mapping post-hypoxic tumor cells reveals a ROS-resistant phenotype that promotes metastasis [J]. Nature Communications, 2019, 10(1).
Nisar H, González P M S, Brauny M, et al. Hypoxia Changes Energy Metabolism and Growth Rate in Non-Small Cell Lung Cancer Cells [J]. Cancers, 2023, 15(9): 2472.
Haga Y, Sakamoto Y, Kajiya K, et al. Whole-genome sequencing reveals the molecular implications of the stepwise progression of lung adenocarcinoma [J]. Nature Communications, 2023, 14(1).
Huang S-F, Liu H-P, Li L-H, et al. High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan [J]. Clinical Cancer Research, 2004, 10(24): 8195–8203.
Zhou F, Guo H, Xia Y, et al. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer [J]. Nature Reviews Clinical Oncology, 2024.
Shi Z, Zheng X, Shi R, et al. Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma [J]. Scientific Reports, 2017, 7(1).
Jin Y, Chen M, Yu X. Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer [J]. Scientific Reports, 2016, 6(1).
Shi Z, Zheng X, Shi R, et al. Score for lung adenocarcinoma in China with EGFR mutation of exon 19 [J]. Medicine, 2018, 97(38): e12537.
Xu J, Yang Y, Gao Z, et al. Distinguishing EGFR mutation molecular subtypes based on MRI radiomics features of lung adenocarcinoma brain metastases [J]. Clinical Neurology and Neurosurgery, 2024, 240: 108258.
Nilsson M B, Robichaux J, Herynk M H, et al. Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype [J]. Journal of Thoracic Oncology, 2021, 16(3): 439–451.
Tamirat M Z, Koivu M, Elenius K, et al. Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation [J]. PLOS ONE, 2019, 14(9): e0222814.
Zhao F N, Zhao Y Q, Han L Z, et al. Clinicoradiological features associated with epidermal growth factor receptor exon 19 and 21 mutation in lung adenocarcinoma. Clinical Radiology, 2019, 74(1): 80.e7-80.e17.
You L, Zheng X, Deng D, et al. The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study [J]. Scientific Reports, 2022, 12(1).
Rahman M A, Yadab M K, Ali M M. Emerging Role of Extracellular pH in Tumor Microenvironment as a Therapeutic Target for Cancer Immunotherapy [J]. Cells, 2024, 13(22): 1924.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Min Li, Zhenfeng Wang, Qiang Zhang
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
